Clinical Trials Browser

Biliary Tract Neoplasms

NCT04502602 2026-05-11

iNNOVATE

Phase 1 Active not recruiting

18 enrolled

Gynecologic

Ovarian Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04374305 2026-05-06

INTUITT-NF2

Phase 2 Recruiting

109 enrolled

CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2 Recruiting

83 enrolled

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Active not recruiting

34 enrolled

Breast

Breast Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast

Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 2 Recruiting

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Phase 1/2 Active not recruiting

14 enrolled

CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Phase 2 Recruiting

460 enrolled

CNS

Glioblastoma

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Phase EARLY_PHASE1 Recruiting

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

300 enrolled

Breast

Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2 Recruiting

30 enrolled

Carcinoma, Lobular

NCT07152782 2025-09-03

THUNDER

Phase 2 Not yet recruiting

202 enrolled

Breast

Breast Cancer With Brain Metastasis

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2 Completed

11 enrolled 12 charts

Breast

Breast Neoplasms

Clinical Trials

SAFIR-ABC10

iNNOVATE

I-SPY

INTUITT-NF2

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

THUNDER

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib